Real Estate Marketplace Turned Crypto Play Skyrockets 842%

Good Afternoon! 

Hey, everyone. It's Adam from Elite Trade Club. Here’s what moved the market today.

Elon Musk’s created a whole group of “Teslanaires”... His companies are worth more than $2 trillion combined... And the small companies connected to his breakthroughs have soared.

Now, as early as June 1, Tesla is set to launch its initial fleet of self-driving robotaxis —  and Elon believes what’s coming could create “the biggest asset value appreciation in history.”

Silicon Valley insider Jeff Brown’s sharing all the details in The Robotaxi Emergency Briefing – including the name of one of his top picks.

Click here to register for the event.

US stocks extended losses amid one of the most dramatic selloffs in years, but the benchmark indices rebounded by the end of the session, and the Nasdaq even closed with a plus. Investors hope that Trump’s tariffs will become more flexible.

Mesa Air Group Inc. (NASDAQ: MESA) has announced a definitive merger with Republic Airways Holdings Inc., forming a larger regional airline under the Republic name. Depending on pre-closing milestones, the all-stock deal assigns Mesa shareholders between 6% and 12% ownership in the combined company. Republic shareholders will control the remaining equity.

Investors responded strongly to the announcement, with Mesa shares posting a sharp surge following the news. The market reaction reflected confidence in the combined airline's expanded footprint and potential synergies.

Mesa will retain operational contracts with major carriers, including United Airlines, which supports the transition by backing required asset divestments. The agreement excludes any outstanding debt transfer from Mesa to the merged company.

Once finalized, the merged airline will operate around 310 Embraer jets and perform over 1,250 daily departures. Mesa and Republic will maintain their current FAA certificates until a unified operating license is approved.

The new entity's administration will come from the Republic's executive team. The board will include six Republic directors and one appointed by Mesa.

The companies expect the transaction to close later this year, pending regulatory approvals.

The deal positions Mesa for long-term stability while contributing to one of North America's largest regional aviation platforms.

On Behalf of Azincourt Energy Corp

Five years ago, Uranium Energy Corp. (UEC) was a small uranium junior trading at just $0.60.

Most investors ignored it.

Then, the uranium market exploded.

UEC’s stock skyrocketed 2,500 percent, transforming early investors into millionaires.

Now, the market is hunting for the next UEC.

One tiny uranium junior is sitting on prime assets in the world’s richest uranium region.

Drill results confirm uranium mineralization, with more exploration underway.

Global nuclear expansion is fueling long-term demand for uranium.

The US is desperate for domestic uranium supply—creating a major opportunity.

With billionaire-backed nuclear investments and a global energy crunch, this company could be the next big uranium success story.

Find out why investors are paying attention to this stock.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

Johnson & Johnson (NYSE: JNJ) announced that its monoclonal antibody Tremfya (guselkumab) met primary and major secondary endpoints in the Phase IIIb APEX trial for adults with active psoriatic arthritis (PsA). The study enrolled biologic-naïve participants who had shown inadequate response to standard therapies.

The trial evaluated Tremfya’s ability to reduce the signs and symptoms of PsA over 24 weeks compared to placebo. Results demonstrated that the treatment slowed structural joint damage based on the PsA-modified van der Heijde-Sharp (vdH-S) scoring system, which includes joint space narrowing and erosion subscores.

Researchers designed the study with an initial 24-week double-blind treatment period, followed by 24 weeks of active therapy and an additional 12-week safety follow-up. Participants moving into the long-term extension will undergo two additional years of active treatment, with final safety data collected after that period.

Tremfya targets interleukin-23 (IL-23) and binds to CD64. Data from the APEX trial remained consistent with the therapy’s known safety profile. No new safety signals emerged during the trial period.

Psoriatic arthritis affects joints through stiffness, swelling, and pain. Clinical trials involving Tremfya continue to support its role in addressing inflammatory symptoms and structural joint outcomes.

Johnson & Johnson continues to advance its immunology pipeline with ongoing research and development for approved and investigational indications across inflammatory diseases.

In 2011, Silicon Valley insider Jeff Brown rode in an early self-driving car…

In 2018, he recommended Tesla…

And last year, he blindfolded himself in a Cybertruck to show that Tesla’s self-driving technology was ready for prime time.

Now the day has come.

As early as June 1, Tesla is set to launch its initial fleet of self-driving robotaxis. And for a limited time, you have the chance to get ahead of the small companies set to soar.

On Thursday, April 10, at 1 p.m. ET, Jeff’s sharing the details in The Robotaxi Emergency Briefing — including the name of one of his top picks completely FREE.

Register here now.

Chevron Corporation (NYSE: CVX) has received a jury verdict requiring the company to pay $745 million in damages related to long-term environmental impacts in Louisiana. The ruling follows a legal dispute by Plaquemines Parish concerning legacy operations tied to Texaco, which Chevron acquired in 2000.

Jurors awarded $575 million for land loss, $161 million for contamination, and $8.6 million for abandoned equipment. The verdict centers on activities in the Breton Sound area, where the plaintiff alleged that oil and gas infrastructure contributed to coastal degradation. 

State regulations enacted in 1980 requiring operators to restore affected wetlands were at the case's core. Chevron argued that much of the activity occurred before implementing these requirements and plans to appeal the verdict.

The case forms part of a broader set of legal actions filed by multiple Louisiana parishes against energy companies. The actions focus on historical compliance with environmental permitting and land use responsibilities. The decision could influence similar lawsuits currently pending across the state.

Plaquemines Parish sought a larger award but will move forward with the jury’s decision as the next phase of the case proceeds.

Chevron continues to operate in Louisiana and maintains that its operations comply with applicable laws during relevant periods.

Janover Inc [JNVR] $37.71 (+842.97%)

Janover closed Friday at $4.00, and today it broke above $48.00, showing one of the craziest bull runs. The commercial mortgage platform is now a crypto play after former Kraken executives acquired majority ownership of the company and planned to buy Solana for its digital asset treasury strategy.

Rhythm Pharmaceuticals Inc [RYTM] $54.96 (+17.06%)

Rhythm Pharmaceuticals recovered from its lowest level since September after the company announced that its drug for rare obesity met the key target of a Phase 3 trial. RYTM will seek to expand approval in the US and Europe.

United States Steel Corp [X] $44.50 (+16.22%)

United States Steel saw its shares increase to the highest level in a year after Donald Trump asked the Committee on Foreign Investment in the US to review the company’s blocked acquisition by Nippon Steel. Previously, the Biden administration halted the $14.1 billion deal on national security concerns.

American Rebel Holdings [AREB] $10.61 (-45.59%)

American Rebel became the worst performer on Monday after losing nearly half of its value following last week’s massive rally. The company issued a corporate update that didn’t impress investors.

Quanterix Corp [QTRX] $5.17 (-12.96%)

Quanterix, a life sciences company, plunged to its record low after a major shareholder criticized the company for carrying out a $30 million bridge loan to Akoya Biosciences [AKYA] ahead of a shareholder vote on their proposed merger. The investor claims the financing exposes shareholders to undue risk and lacks proper disclosure.

Apollomics Inc [APLM] $5.09 (-14.31%)

Biopharmaceutical company Apollomics also tumbled to its record low after investors found out that the company had exited its immuno-oncology partnership with TYG Oncology to cut costs and extend its runway into early 2026. The move shows APLM’s financial distress and limited progress in several key programs.

On Behalf of Azincourt Energy Corp

Something big is brewing in the uranium market.

And the world’s wealthiest, most powerful investors are moving in—Bill Gates, Jeff Bezos, and Sam Altman.

They’ve made their billions in tech revolutions like Amazon, Microsoft, and OpenAI. Now, they’re betting big on nuclear energy.

Governments are following suit. The US just poured $6 billion into nuclear energy, while the Trump administration is fast-tracking policies to boost domestic uranium production.

For investors, this is a perfect storm.

The last uranium boom turned a tiny $0.60 stock into a $3.11 billion powerhouse.

The next one could be happening right now.

Find out which uranium junior could be the next big winner.

*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.

That's it for today! Please, write us back, and let us know what you think of the Closing Bell Roundup. We're always eager to hear feedback!

Thanks for reading. I'll see you at the next open! 

Best Regards,
— Adam G.
Elite Trade Club

Click here to get our daily newsletter straight to your cell for free.

P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.

*Standard message/carrier rates may apply.

Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.